LONZA GROUP UNSP.ADR 1/10 (LO3A) - Total Liabilities
Based on the latest financial reports, LONZA GROUP UNSP.ADR 1/10 (LO3A) has total liabilities worth €9.94 Billion EUR (≈ $11.62 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check LO3A asset resilience ratio to evaluate the company's liquid asset resilience ratio.
LONZA GROUP UNSP.ADR 1/10 - Total Liabilities Trend (2022–2025)
This chart illustrates how LONZA GROUP UNSP.ADR 1/10's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see LO3A asset base.
LONZA GROUP UNSP.ADR 1/10 Competitors by Total Liabilities
The table below lists competitors of LONZA GROUP UNSP.ADR 1/10 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Toyota Tsusho Corp
NYSE:TYHOY
|
USA | $4.73 Trillion |
|
RECRUIT HLD.UNSP.ADR/02
F:1RHA
|
Germany | €1.14 Trillion |
|
Mahindra & Mahindra Limited
NSE:M&M
|
India | Rs2.08 Trillion |
|
Heineken
AS:HEIA
|
Netherlands | €36.34 Billion |
|
KB Financial Group
KO:105560
|
Korea | ₩768.60 Trillion |
|
Wuliangye Yibin Co Ltd
SHE:000858
|
China | CN¥34.87 Billion |
|
KB Financial Group Inc
NYSE:KB
|
USA | $738.87 Trillion |
|
Bayerische Motoren Werke Aktiengesellschaft
XETRA:BMW
|
Germany | €166.41 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down LONZA GROUP UNSP.ADR 1/10's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of LONZA GROUP UNSP.ADR 1/10 to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.89 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.56 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LONZA GROUP UNSP.ADR 1/10's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LONZA GROUP UNSP.ADR 1/10 (2022–2025)
The table below shows the annual total liabilities of LONZA GROUP UNSP.ADR 1/10 from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €9.78 Billion ≈ $11.43 Billion |
-5.46% |
| 2024-12-31 | €10.35 Billion ≈ $12.09 Billion |
+41.02% |
| 2023-12-31 | €7.34 Billion ≈ $8.58 Billion |
+9.64% |
| 2022-12-31 | €6.69 Billion ≈ $7.82 Billion |
-- |
About LONZA GROUP UNSP.ADR 1/10
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics; Small Molecules; Cell & Gene; and Capsules & Health Ingredients segments. The Biologics segment engages in the contract develo… Read more